



SAFETY DATA SHEET

Revision date: 12-Apr-2015

Version: 2.2

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Methylprednisolone Tablets

Trade Name: MEDROL
Chemical Family: Corticosteroid hormone

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anti-inflammatory

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
Animal Health Division (office hours): +44 (0)1737 331333

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A
Specific target organ systemic toxicity (repeated exposure): Category 2

EU Classification:

EU Indication of danger: Toxic to reproduction: Category 1
Harmful

EU Risk Phrases:

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.
R61 - May cause harm to the unborn child.

Label Elements

Signal Word: Danger
Hazard Statements: H360 - May damage fertility or the unborn child
H373 - May cause damage to organs through prolonged or repeated exposure: blood and blood forming organs, adrenal gland

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 2 of 10
Version: 2.2



Other Hazards
Australian Hazard Classification (NOHSC):

No data available
Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Methylprednisolone	83-43-2	201-476-4	Xn;R48/22 Repr.Cat.1;R61	Repr. 1A (H360) STOT RE 2 (H373)	2, 4, 8, 16 or 32mg***
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*
Calcium stearate	1592-23-0	216-472-8	Not Listed	Not Listed	*
Mineral oil	8012-95-1	232-384-2	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sorbic acid	110-44-1	203-768-7	Not Listed	Not Listed	*
Lactose	63-42-3	200-559-2	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 3 of 10
Version: 2.2

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: May include oxides of carbon.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

METHYLPREDNISOLONE TABLETS

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 4 of 10
Version: 2.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Methylprednisolone

Pfizer OEL TWA-8 Hr: 4 µg/m³, Skin

Corn Starch

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Czech Republic OEL - TWA 4.0 mg/m³
Greece OEL - TWA 10 mg/m³
Ireland OEL - TWAs 5 mg/m³
Ireland OEL - TWAs 10 mg/m³
OSHA - Final PELs - TWAs: 4 mg/m³
Portugal OEL - TWA 15 mg/m³
Slovakia OEL - TWA 10 mg/m³
Spain OEL - TWA 4 mg/m³
Switzerland OEL - TWAs 10 mg/m³
Switzerland OEL - TWAs 3 mg/m³

Sucrose

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³
Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 10 mg/m³
OSHA - Final PELs - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Slovakia OEL - TWA 6 mg/m³
Spain OEL - TWA 10 mg/m³

Calcium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Mineral oil

ACGIH Threshold Limit Value (TWA) 5 mg/m³
Australia TWA 5 mg/m³
Belgium OEL - TWA 5 mg/m³
Bulgaria OEL - TWA 5.0 mg/m³
Czech Republic OEL - TWA 5 mg/m³
Denmark OEL - TWA 1 mg/m³
Finland OEL - TWA 5 mg/m³
Greece OEL - TWA 5 mg/m³
Lithuania OEL - TWA 1 mg/m³
Netherlands OEL - TWA 5 mg/m³

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 5 of 10
Version: 2.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELs - TWAs:	5 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 mg/m ³
Romania OEL - TWA	5 mg/m ³
Slovakia OEL - TWA	5 ppm
	1 mg/m ³
	5 mg/m ³
Spain OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	Various
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	
Calcium stearate	No data available
Sucrose	No data available
Corn Starch	No data available
Lactose	No data available
Sorbic acid	No data available
Mineral oil	No data available
Methylprednisolone	
Predicted 7.4 Log D 1.99	
Decomposition Temperature (°C):	No data available.

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 6 of 10
Version: 2.2

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May be absorbed through the skin and cause systemic effects.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs. May cause allergic reactions in susceptible individuals following repeated contact with this material.
Known Clinical Effects: Adverse clinical reactions include the development of hypersensitivity and/or irritation leading to rashes, itching, and burning. Clinical use has resulted in hormonal alterations.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD50 29.7 g/kg

Sorbic acid

Rat Oral LD50 7360 mg/kg
Mouse Oral LD50 3200mg/kg

Methylprednisolone

Rat Oral LD 50 > 2000 mg/kg
Mouse Oral LD 50 450mg/kg
Rat Intraperitoneal LD 50 1000mg/kg
Mouse Intraperitoneal LD 50 1409mg/kg
Rat Subcutaneous LD 50 >3000mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 7 of 10
Version: 2.2

11. TOXICOLOGICAL INFORMATION

Irritation / Sensitization: (Study Type, Species, Severity)

Mineral oil

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Methylprednisolone

Skin Irritation Rabbit No effect
Eye Irritation Rabbit No effect
Skin Sensitization - GPMT Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Methylprednisolone

42 Day(s)	Dog	Oral	167 µg/kg/day	LOAEL	Adrenal gland
6 Week(s)	Rat	Subcutaneous	500 µg/kg/day	LOAEL	None identified
14 Week(s)	Rat	Subcutaneous	0.4 µg/kg/day	NOAEL	Blood forming organs, Adrenal gland
52 Week(s)	Rat	Subcutaneous	4 µg/kg/day	NOAEL	Blood forming organs Adrenal gland

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Methylprednisolone

Reproductive & Fertility	Rat	Subcutaneous	0.004 mg/kg/day	NOAEL	Paternal toxicity
Reproductive & Fertility	Rat	Subcutaneous	0.02 mg/kg/day	LOAEL	Fetotoxicity
Embryo / Fetal Development	Rat	Subcutaneous	1.0 mg/kg/day	LOAEL	Fetotoxicity, Teratogenic
Embryo / Fetal Development	Mouse	Intramuscular	330 mg/kg/day	LOAEL	Teratogenic
Embryo / Fetal Development	Rabbit	Intramuscular	0.1 mg/kg/day	LOAEL	Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Methylprednisolone

Bacterial Mutagenicity (Ames) *Salmonella* Negative
Unscheduled DNA Synthesis Rat Hepatocyte Negative
Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative
Direct DNA Interaction Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 8 of 10
Version: 2.2

Bio-accumulative Potential:
Methylprednisolone
Predicted 7.4 Log D 1.99

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

D2a very toxic materials



Methylprednisolone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	201-476-4

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 9 of 10
Version: 2.2

15. REGULATORY INFORMATION

Corn Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

Calcium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	216-472-8

Mineral oil

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-384-2

Sorbic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-768-7

Lactose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-559-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

METHYLPREDNISOLONE TABLETS

SAFETY DATA SHEET

Material Name: Methylprednisolone Tablets
Revision date: 12-Apr-2015

Page 10 of 10
Version: 2.2

Reproductive toxicity-Cat.1A; H360 - May damage fertility or the unborn child
Specific target organ toxicity, single exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure

Xn - Harmful
Toxic to reproduction: Category 1

R61 - May cause harm to the unborn child.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification.

Revision date: 12-Apr-2015
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet